Photo:
utswmed.org
Mar 5, 2026, 15:51
Samer Al Hadidi: Cytopenias and Infection Risk With BCMA-Directed Bispecific Antibodies
Samer Al Hadidi, Associate Professor at UT Southwestern Medical Center, shared a post on LinkedIn:
“The Overlooked Burden of Cytopenias With BCMA-Directed Bispecific Antibodies
Hematologic toxicity is underappreciated:
- 87% of pts: grade 3-4 lymphopenia
- 55% grade 3-4 neutropenia (65% with teclistamab)
- 74% required dose interruptions
- 54.5% needed G-CSF
This is likely one of the important causes of higher grade infections with those agents.
We need to think about preventive strategies given the high efficacy of those agents.”
Stay updated with Hemostasis Today.
-
Jul 28, 2026, 15:00Rucha Patil: Grateful to Contribute to the National Coagulation Conclave 2026
-
Jul 28, 2026, 14:51Islam Aboumoussa: A New Perspective on Dual Antithrombotic Therapy in Stroke Prevention
-
Jul 28, 2026, 14:40Marilena Vrana: Join the Conversation at Plasma Protein Forum 2026
-
Jul 28, 2026, 14:24Jon Wright: Pushing the Boundaries of Hemophilia Care
-
Jul 28, 2026, 14:11Improving Care for People with Bleeding Disorders Through Teamwork – WFH
-
Jul 28, 2026, 14:10Blessing Oluwasanya: When Heavy Periods Are More Than Just an Inconvenience
-
Jul 28, 2026, 13:46Manal Rayyan: Efanesoctocog Alfa Shows Excellent Real-World Performance
-
Jul 28, 2026, 13:22Raelene Kambli: Advocating for Safer Blood Access
-
Jul 28, 2026, 13:07Connie Montgomery: Conversations That Change Hemophilia Care